25 April 2017
News and Views
Links and Services
A study in the latest issue of the Alimentary Pharmacology & Therapeutics evaluates the impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease.
Consequences of latent cytomegalovirus (CMV) infection reactivation on inflammatory bowel disease
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors